Financial Performance - Network Volume increased by 14% from $2331 million in 2Q'24 to $2648 million in 2Q'25 [12] - Total revenue & other income increased by 30% from $250 million in 2Q'24 to $326 million in 2Q'25 [12] - Revenue from fees less production costs (FRLPC) increased by 30% from $97 million in 2Q'24 to $126 million in 2Q'25 [12] - Adjusted EBITDA increased by 72% from $50 million in 2Q'24 to $86 million in 2Q'25 [12] - Net income attributable to Pagaya Technologies Ltd turned positive, from a loss of $75 million in 2Q'24 to a profit of $17 million in 2Q'25 [12] - Adjusted Net Income increased significantly by 604% from $7 million in 2Q'24 to $51 million in 2Q'25 [12] Operating Metrics - Quarterly Application Volume was $238 billion in 2Q'25, with a conversion rate of applications to issued loans of approximately 1% [35] - Investments in loans and securities totaled $870 million as of June 30, 2025 [44] - Securitization Certificates make up 62.9% of the total investments in loans and securities [44] FRLPC Evolution - FRLPC % increased from 4.2% in 2Q'24 to 4.8% in 2Q'25 [56] - The company is targeting FRLPC% in 2025 to be between 4% and 5% [17]

Financial Performance - Sales volume reached 3.3 million tons in 2Q25, compared to 2.7 million tons in 1Q25 and 2.5 million tons in 2Q24[6] - Adjusted EBITDA was R$6.1 billion in 2Q25, versus R$4.9 billion in 1Q25 and R$6.3 billion in 2Q24[6] - Operating cash generation amounted to R$4.1 billion in 2Q25, up from R$2.6 billion in 1Q25 but down from R$4.5 billion in 2Q24[6] - Cash cost ex-downtimes was R$832/ton in 2Q25, compared to R$859/ton in 1Q25 and R$828/ton in 2Q24[6] - Net debt stood at US$13.0 billion in 2Q25, slightly higher than US$12.9 billion in 1Q25 and US$12.0 billion in 2Q24[7] - Leverage was 3.1x in US$ in 2Q25, compared to 3.0x in 1Q25 and 3.2x in 2Q24[7] Pulp and Paper Business - Paper sales were 348 thousand tons in 2Q25, compared to 329 thousand tons in 1Q25 and 270 thousand tons in 2Q24[6] - Pulp sales volume increased to 3,269 thousand tons in 2Q25 from 2,651 thousand tons in 1Q25 and 2,545 thousand tons in 2Q24[12] - Pulp business adjusted EBITDA margin was 52% in 2Q25[12] Financial Management - Notional value of the current portfolio was US$6.8 billion as of June 2025[22]

Third Quarter Fiscal 2025 | Earnings Call August 7, 2025 NYSE: BV Introductory Information Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are subject to the "safe harbor" created by those secti ...

Financial Performance & Guidance - Q2 2025 royalty revenue increased by 57% compared to Q2 2024, driven by Ohtuvayre, Filspari, Qarziba, Capvaxive and Vaxneuvance[3, 26] - Q2 2025 adjusted EPS grew 14% to $1.60[3, 24, 25] - The company increased revenue guidance for 2025 from $180 million-$200 million to $200 million-$225 million, a 13% increase[3, 24, 33] - Adjusted EPS guidance for 2025 was raised from $6.00-$6.25 to $6.70-$7.00 per diluted share, a 12% increase[3, 24, 33] Portfolio & Investments - Ligand has approximately 50% equity interest in Pelthos and is entitled to a 13% royalty on Zelsuvmi sales[3, 6] - The company committed $35 million in long-term capital for royalty interest in Orchestra BioMed's AVIM therapy and Virtue SAB and invested $5 million in equity private placement[3, 20, 21] - Merck is set to acquire Verona for $10 billion, which will impact Ligand's 3% royalty on Ohtuvayre[3, 4, 8] Strategic Outlook - The company anticipates a long-term royalty revenue CAGR of greater than 22%[3, 27] - Ohtuvayre peak-sales consensus updated from $1.2 billion in December 2024 to $3.4 billion in August 2025[30] - Ligand has ~$450 million in deployable capital as of June 30, 2025[3, 24]

Q2 2025 Performance Highlights - Revenues reached $391 million, a 1.5% year-over-year growth assuming the Sterling acquisition occurred on 1/1/2023[21, 23] - Adjusted EBITDA was $114 million, resulting in a 29.2% Adjusted EBITDA Margin[21] - Adjusted Net Income amounted to $47 million with an Adjusted Diluted EPS of $0.27[21] - Adjusted Operating Cash Flow was $47.7 million after adjusting for $10.4 million in Sterling acquisition and integration costs[23, 49] Synergy Realization and Cost Management - $47 million in run-rate synergies were actioned as of June 30, 2025, progressing towards a total run rate synergy target of $65 million to $80 million within 2 years[38, 69] - $18 million in year-to-date synergies were realized as of June 30, 2025[38] - Debt was repriced in July, reducing the borrowing rate by 50 bps, leading to approximately $10 million in annual cash interest savings[49] Financial Outlook and Capital Structure - Full year 2025 revenue guidance is reaffirmed at $1.5 billion to $1.6 billion[53] - Full year 2025 Adjusted EBITDA guidance is reaffirmed at $410 million to $450 million, with an Adjusted EBITDA Margin of approximately 27% to 28%[53] - Full year 2025 Adjusted Net Income is projected to be $152 million to $182 million, with Adjusted Diluted Earnings Per Share of $0.86 to $1.03[53] - Net leverage is targeted to reach approximately 2-3x within 24 months post-closing, with total debt repayments exceeding $45 million since closing[46, 47]

Financial Performance - Enovis reported a net sales increase to $565 million in Q2 2025, compared to $525 million in Q2 2024[20] - Adjusted Earnings Per Share (EPS) increased by 27% in Q2 2025[8] - The adjusted gross profit margin improved from 59.6% in Q2 2024 to 60.5% in Q2 2025[20] - Adjusted EBITDA for Q2 2025 was $97 million, compared to $90 million in Q2 2024, maintaining a margin of 17.2%[20] - For the first half of 2025, net sales reached $1.123 billion, up from $1.041 billion in the first half of 2024[20] - Adjusted EPS for the first half of 2025 was $1.60, compared to $1.13 in the first half of 2024[20] Segment Performance - Reconstructive segment sales grew by 11% year-over-year, with 8% organic growth, reaching $274 million in Q2 2025[10] - Prevention & Recovery (P&R) segment sales grew by 5% year-over-year, with 3% organic growth, reaching $291 million in Q2 2025[15] - Extremities within the Reconstructive segment experienced 10% growth[14] Outlook - Enovis raised its full-year 2025 revenue outlook to $2.245-$2.275 billion[22] - The company anticipates organic growth of approximately 6.25-6.75% year-over-year[25]

Financial Performance - Q2 2025 total revenues were $3582 million, a decrease of 6% compared to Q2 2024[39] - Adjusted EBITDA for Q2 2025 was $1079 million, an 11% decrease compared to Q2 2024[39] - Adjusted EPS for Q2 2025 was $062, a 10% decrease compared to Q2 2024[39] - Free cash flow for Q2 2025 was $167 million, or $241 million excluding transaction-related costs[39, 40] Impact of Indore Facility - The estimated negative impact on 2025 total revenues due to the Indore facility is approximately $500 million, with an estimated $385 million impact on adjusted EBITDA[2, 58] - The Q2 2025 Indore impact to earnings from operations and adjusted EBITDA is estimated to be approximately $110 million[58, 60] - Estimated 2025 net sales impact by region due to the Indore facility: North America ~$300 million, Europe ~$75 million, and Emerging Markets ~$125 million[2, 58] Financial Guidance - The company reaffirms its 2025 financial guidance, with total revenues expected to be between $135 billion and $140 billion[2, 63] - Adjusted EBITDA is expected to be between $389 billion and $419 billion, and adjusted EPS is expected to be between $216 and $230[2, 63] - The company expects to complete share repurchases totaling between $500 million and $650 million in 2025[2] Business Segment Performance - Developed Markets net sales were $2119 million, a decrease of 9% compared to Q2 2024[46] - Emerging Markets net sales were $555 million, a decrease of 4% compared to Q2 2024[49] - Greater China net sales were $589 million, an increase of 9% compared to Q2 2024[55]

Financial Performance & Outlook - Q2 2025 revenues reached $78 million, with Thermal Barrier revenues accounting for $55.2 million, a 13% QoQ increase[9] - Energy Industrial maintained gross margins of 35%+ on revenues of $22.8 million in Q2 2025[9] - Adjusted EBITDA for Q2 2025 was $9.7 million, reflecting ~2X QoQ growth on similar revenues[9] - The company anticipates a ~2X improvement in Adjusted EBITDA on similar revenue in H2 2025[8] - H2 2025 revenue is projected to be in the range of $140 million to $160 million, with Adjusted EBITDA between $20 million and $30 million[7,8,12] - Full year 2025 Adjusted EBITDA is projected to be $35 million to $45 million[12] Cost Management & Capital Expenditure - Fixed cost reductions are expected to drive improved financial performance in H2 2025[6] - CAPEX spend in Q2 2025 was reduced by 50% YoY due to demobilizing Plant II and EV Thermal Barrier Equipment[9] - CAPEX for H2 2025 is projected at $10 million, leading to a full year CAPEX of $25 million[12] Electric Vehicle (EV) Market - General Motors (GM) is gaining EV market share in the US[21] - GM's North American EV production forecast for 2025 is approximately 241,000 units[24] - The Equinox model is expected to represent ~24% of GM's total EV volume in 2026[26]

Financial Performance - Q2 2025 revenue reached $345.3 million, an 11% year-over-year increase[9] - Q2 2025 Center Margin was $108.4 million, representing 31.4% of revenue[9] - Q2 2025 Adjusted EBITDA was $34.0 million, or 9.8% of revenue[9] - The company ended Q2 2025 with a cash position of $188.9 million[9] - Full year 2025 revenue guidance is reaffirmed at $1.40 billion - $1.44 billion[19] - Full year 2025 Adjusted EBITDA guidance is raised to $140 million - $150 million[19] Operational Metrics - Total clinicians reached 7,708, an 11% year-over-year growth, with 173 net clinician additions in Q2[9, 8] - Q2 2025 visit volumes increased by 12% year-over-year to 2.2 million[9] - The company operates over 550 centers in 33 states[8] Balance Sheet and Capital Allocation - Cash and cash equivalents totaled $189 million[17] - Net long-term debt is $273 million[17]

Financial Highlights - H1 2025 Adjusted OIBDA reached $08 billion, reflecting an 8% rebased growth YoY[8] - H1 2025 Adjusted OIBDA less P&E Additions was $06 billion[8] - H1 2025 revenue totaled $22 billion[8] - Q2 2025 Adjusted OIBDA increased by 7% rebased growth rate[69] - Q2 2025 P&E additions accounted for 14% of revenue, a 16% YoY decrease[69] Subscriber Growth - H1 2025 saw a net addition of over 100,000 subscribers, excluding LPR, with Costa Rica, Panama, and Jamaica as main contributors[8] - H1 2025 witnessed 70,000 net additions in Internet and Postpaid subscribers[8] Segment Performance - C&W credit silo revenue increased by 6% YoY[72] - Liberty Networks wholesale revenue (excluding IRUs) increased by 8% rebased[33] - Liberty Puerto Rico's Adjusted OIBDA increased by 21%[77] - Liberty Costa Rica's mobile revenue increased by 5% rebased YoY[85] Strategic Initiatives - The company intends to separate LPR from LLA and focus on liability management in Puerto Rico[8] - LLA is focused on capital allocation and shareholder value, including potential spin-off of Puerto Rico and recurring dividends or share repurchases[91]